972 related articles for article (PubMed ID: 28826184)
21. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
[TBL] [Abstract][Full Text] [Related]
22. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
Podhorna J; Krahnke T; Shear M; Harrison JE;
Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
[TBL] [Abstract][Full Text] [Related]
24. Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease.
Johansson P; Åberg D; Johansson JO; Mattsson N; Hansson O; Ahrén B; Isgaard J; Åberg ND; Blennow K; Zetterberg H; Wallin A; Svensson J
Psychoneuroendocrinology; 2013 Sep; 38(9):1729-37. PubMed ID: 23473966
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
Mroczko B; Groblewska M; Zboch M; Muszyński P; Zajkowska A; Borawska R; Szmitkowski M; Kornhuber J; Lewczuk P
J Alzheimers Dis; 2015; 43(3):1031-7. PubMed ID: 25159667
[TBL] [Abstract][Full Text] [Related]
26. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
Vos S; van Rossum I; Burns L; Knol D; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Handels R; L'Italien G; van der Flier W; Aalten P; Teunissen C; Barkhof F; Blennow K; Wolz R; Rueckert D; Verhey F; Visser PJ
Neurobiol Aging; 2012 Oct; 33(10):2272-81. PubMed ID: 22264648
[TBL] [Abstract][Full Text] [Related]
27. Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition.
Reijs BLR; Ramakers IHGB; Elias-Sonnenschein L; Teunissen CE; Koel-Simmelink M; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Johannsen P; Vanderstichele H; Verhey F; Devanand DP; Visser PJ
J Alzheimers Dis; 2017; 60(3):1025-1034. PubMed ID: 28984603
[TBL] [Abstract][Full Text] [Related]
28. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
29. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.
Niemantsverdriet E; Goossens J; Struyfs H; Martin JJ; Goeman J; De Deyn PP; Vanderstichele H; Engelborghs S
J Alzheimers Dis; 2016; 51(1):97-106. PubMed ID: 26836187
[TBL] [Abstract][Full Text] [Related]
31. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.
Álvarez I; Aguilar M; González JM; Ysamat M; Lorenzo-Bosquet C; Alonso A; Tartari JP; Romero S; Diez-Fairen M; Carcel M; Pujalte F; Pastor P
J Alzheimers Dis; 2018; 61(1):135-143. PubMed ID: 29154286
[TBL] [Abstract][Full Text] [Related]
32. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.
Somers C; Struyfs H; Goossens J; Niemantsverdriet E; Luyckx J; De Roeck N; De Roeck E; De Vil B; Cras P; Martin JJ; De Deyn PP; Bjerke M; Engelborghs S
J Alzheimers Dis; 2016 Aug; 54(1):383-95. PubMed ID: 27567807
[TBL] [Abstract][Full Text] [Related]
33. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.
Da X; Toledo JB; Zee J; Wolk DA; Xie SX; Ou Y; Shacklett A; Parmpi P; Shaw L; Trojanowski JQ; Davatzikos C;
Neuroimage Clin; 2014; 4():164-73. PubMed ID: 24371799
[TBL] [Abstract][Full Text] [Related]
34. Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
Wolfsgruber S; Polcher A; Koppara A; Kleineidam L; Frölich L; Peters O; Hüll M; Rüther E; Wiltfang J; Maier W; Kornhuber J; Lewczuk P; Jessen F; Wagner M
J Alzheimers Dis; 2017; 58(3):939-950. PubMed ID: 28527210
[TBL] [Abstract][Full Text] [Related]
35. Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.
Alexopoulos P; Werle L; Roesler J; Thierjung N; Gleixner LS; Yakushev I; Laskaris N; Wagenpfeil S; Gourzis P; Kurz A; Perneczky R;
Alzheimers Res Ther; 2016 Dec; 8(1):51. PubMed ID: 27931251
[TBL] [Abstract][Full Text] [Related]
36. CSF Apo-E levels associate with cognitive decline and MRI changes.
Toledo JB; Da X; Weiner MW; Wolk DA; Xie SX; Arnold SE; Davatzikos C; Shaw LM; Trojanowski JQ;
Acta Neuropathol; 2014 May; 127(5):621-32. PubMed ID: 24385135
[TBL] [Abstract][Full Text] [Related]
37. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
38. Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment.
Gonzales MM; Insel PS; Nelson C; Tosun D; Schöll M; Mattsson N; Sacuiu S; Bickford D; Weiner MW; Mackin RS;
Int J Geriatr Psychiatry; 2018 Oct; 33(10):1305-1311. PubMed ID: 29953668
[TBL] [Abstract][Full Text] [Related]
39. Interactions between amyloid-β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease.
Kristofikova Z; Ricny J; Kolarova M; Vyhnalek M; Hort J; Laczo J; Sirova J; Ripova D
J Alzheimers Dis; 2014; 42 Suppl 3():S91-8. PubMed ID: 24670397
[TBL] [Abstract][Full Text] [Related]
40. Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine.
Chiasserini D; Biscetti L; Farotti L; Eusebi P; Salvadori N; Lisetti V; Baschieri F; Chipi E; Frattini G; Stoops E; Vanderstichele H; Calabresi P; Parnetti L
J Alzheimers Dis; 2016 Jul; 54(1):55-67. PubMed ID: 27447425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
